Novo Nordisk Fair Value
NO
The fair market value of NOVO B.CO stock is 696.81 DKK. Relative to the market price of 745.7 DKK Novo Nordisk is overvalued by 4.5%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Novo Nordisk Valuation
Current NOVO B.CO share ticker price is 745.7 DKK.
The fair value level of 696.81 DKK can be considered as an effective entry point for long-term investors to start investing in NOVO B.CO stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 7% higher its fair value
Current price is 36% higher its minimum value
Current price is 12% lower its maximum value
Market price:
NOVO B.CO stock is overvalued
It means the current price may concern as a Risky Entry Point
Novo Nordisk A/S Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
32.43
2
Median P/E over 5 years
27.02
3
Minimum P/E over 5 years
18.64
4
Earning per share (last 12 months)
25.79 DKK
Maximum value
1
x
4
=
836.25 DKK
Fair value
2
x
4
=
696.81 DKK
Minimum value
3
x
4
=
480.58 DKK
Novo Nordisk A/S price metrics
32.27
Annual return (geometric mean)
28.15
Risk (standard deviation) of returns
β
1.37
Beta (volatility compared to market)